QT Imaging Clears FDA for Enhanced Breast Acoustic CT Scanner
Event summary
- QT Imaging received FDA 510(k) clearance for an enhanced configuration of its Breast Acoustic CT scanner on March 10, 2026.
- The updated design features a tilted transmitter geometry to improve imaging coverage of posterior breast tissue near the chest wall.
- The scanner generates 3D tomographic images using reflection-mode and transmission-mode ultrasound data.
- The technology quantifies fibroglandular tissue volume (FGV) and the ratio of fibroglandular tissue to total breast volume (TBV).
The big picture
QT Imaging's FDA clearance for its enhanced Breast Acoustic CT scanner addresses a critical gap in posterior breast imaging, an area often challenging to capture with standard approaches. This strategic move aligns with the broader industry trend towards safer, radiation-free imaging technologies, potentially expanding the company's market reach and diagnostic utility. The ability to quantify fibroglandular tissue volume and ratios provides valuable insights for breast health assessment, positioning QT Imaging as a key player in the evolving landscape of breast cancer detection and management.
What we're watching
- Market Adoption
- How the enhanced imaging coverage will affect the scanner's adoption in clinical settings, particularly for patients with dense breast tissue.
- Competitive Positioning
- Whether QT Imaging can leverage this FDA clearance to strengthen its position against competitors in the radiation-free breast imaging market.
- Commercialization Pace
- The pace at which QT Imaging can scale manufacturing and commercialize the updated scanner configuration.